logo
ENع
#

Latest news with #CVM

Trinity Health Foundation awards scholarships to 26 students
Trinity Health Foundation awards scholarships to 26 students

Yahoo

time26-05-2025

  • Health
  • Yahoo

Trinity Health Foundation awards scholarships to 26 students

Thanks to the generosity of Cardiovascular Medicine, PLLC (CVM) and the endowed fund established by CVM physicians at the Trinity Health Foundation, scholarships were awarded to area students pursuing undergraduate degrees in math, science or medical sciences, according to a news release. This year, 26 students were awarded scholarships totaling $55,000. Since 2008, the fund has provided more than $500,000 in scholarships to area students. CVM cardiologists endow more than $1 million toward a scholarship fund that has awarded more than $500,000 in scholarships to local students. 'We are honored to have the opportunity to award these wonderful students with a scholarshipand advance the future of medicine and science,' says Sanjeev Puri, MD, president ofCardiovascular Medicine, PLLC. 'These scholarships will go a long way in providing ourstudents with the tools to become successful physicians, engineers and scientists.' 'We are deeply grateful to the physicians of Cardiovascular Medicine for their ongoinginvestment in our community's youth,' says Mary Macumber Schmidt, president of Trinity HealthFoundation. 'Their generosity not only eases the financial burden of education but also inspiresa new generation to pursue careers in science, medicine and technology.' The CVM Youth Mentoring Scholarship was created by cardiologists at Cardiovascular Medicine, PLLC, to support and advance quality cardiac patient care through education and research and to promote and encourage excellence in math and sciences. Here are the scholarship recipients: Cohen Callaway – Davenport North High School Anna Carroll – Rockridge High School Madison Carroll – Rock Island High School Allison Casel – Assumption High School Joseph Casel – Assumption High School Laura Chen – Pleasant Valley High School Elizabeth Churchill – Sherrard High School Jenna Copeland – Sherrard High School Olivia Dillavou – Mercer County High School Alexis Dunsworth – Davenport North High School Josephina Gaura – Pleasant Valley High School Maddux Harksen – Spoon River College Sarah Hess – Mercer County High School Cael Hinde – Purdue University Aerielle Johnson – Pleasant Valley High School Madilyn Lair – United Junior Senior High School Alyssa Layer – Sherrard High School Brooklyn Lininger – Mercer County High School Zamzam Mohammed – Trinity College of Nursing & Health Sciences September Naing – Rock Island High School Emily Pearson – Trinity College of Nursing & Health Sciences Grace Ruedy – Pleasant Valley High School Addison Snodgrass – Geneseo High School Kamrin Varela – Trinity College of Nursing & Health Sciences Rylee Warpehoski – University of Missouri (Columbia) Alexia Zenk – Mercer County High School Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Pricing of Public Offering

Yahoo

time22-05-2025

  • Business
  • Yahoo

CEL-SCI Announces Pricing of Public Offering

VIENNA, Va., May 22, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $2.50 per share. Total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, are expected to be $5,000,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments at the public offering price, less the underwriting discount. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine*, for general corporate purposes, and working capital. ThinkEquity is acting as sole book-running manager for the offering. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-265995), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 1, 2022 and declared effective on July 15, 2022. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study. The study will enroll 212 newly diagnosed locally advanced primary treatment naïve resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities law. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. View source version on Contacts COMPANY CONTACT:Gavin de WindtCEL-SCI Corporation(703) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cel-Sci: Fiscal Q2 Earnings Snapshot
Cel-Sci: Fiscal Q2 Earnings Snapshot

Yahoo

time14-05-2025

  • Business
  • Yahoo

Cel-Sci: Fiscal Q2 Earnings Snapshot

VIENNA, Va. (AP) — VIENNA, Va. (AP) — Cel-Sci Corp. (CVM) on Wednesday reported a loss of $6.6 million in its fiscal second quarter. On a per-share basis, the Vienna, Virginia-based company said it had a loss of 8 cents. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on CVM at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store